Dec 11, 2023 | Jack Aiello, SGL Blogs
The morning started by meeting with Takeda, one of our IMF’s generous sponsors enabling several of us to attend ASH; the other 4 sponsors are BMS (Celgene), Janssen, Karyopharm, and Regeneron. We are so thankful for their support. Next, I attended an Education session...
Dec 10, 2023 | Diane Hunter, SGL Blogs
It is said, “to everything there is a season.” My understanding of this is that the situations and circumstances that we go through are not coincidental; they occur at the appointed or appropriate time and they are intentional with great purpose. I believe we...
Dec 10, 2023 | Linda Huguelet, SGL Blogs
Being able to access each myeloma patient individually and select the treatment path that is most effective is my definition of precision medicine. While the 65th Annual American Society of Hematology Conference and Exposition (ASH) is filled with abstracts about...
Dec 10, 2023 | Jack Aiello, SGL Blogs
Today began at 6:30 a.m. PST for the privilege of being able to attend the International Myeloma Working Group (IMWG) meeting. The IMWG has about 300 myeloma specialists who meet twice a year. Whenever you see a phrase such as “…responses per IMWG guidelines,” writing...
Dec 10, 2023 | Jessie Daw, SGL Blogs
Saturday is the first full day at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, and several good sessions on smoldering multiple myeloma (SMM) were presented. In this blog, I want to focus on three study updates and conclude with some...
Dec 10, 2023 | Barbara Davis, SGL Blogs
Day 1 Blog 1 What a day! I attended (watched and listened) to 18 presentations about myeloma. From monoclonal gammopathy of undetermined significance (MGUS) to smoldering multiple myeloma to stage III high-risk patients. I wish I could have lingered after each talk...
